Entering text into the input field will update the search result below

Acadia Q1 Nuplazid sales up 29%

  • ACADIA Pharmaceuticals (NASDAQ:ACAD) Q1 results ($M): NUPLAZID sales: 63.0 (+28.8%).
  • Net loss: (85.3) (-57.1%); loss/share: (0.59) (-31.8%).
  • 2019 guidance: NUPLAZID sales: $280M - 300M.
  • Previously: ACADIA Pharma misses by $0.07, beats on revenue (May 1)

Recommended For You

About ACAD Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
ACAD--
ACADIA Pharmaceuticals Inc.